Raymond James Names Top 3 Picks in Beauty Stocks

Raymond James named Estée Lauder and Ulta its two top beauty-sector picks, citing Estée Lauder’s return to growth in fiscal 2026 and expected further profit growth in fiscal 2027, alongside Ulta’s resilience and raised full-year guidance. Both stories carry caveats: Estée Lauder’s recovery is measured against a low base and its valuation prices in growth, while Ulta’s second-half outlook implies slower growth and category performance is uneven. E.l.f. Beauty ranked close behind, with Rhode and international sales driving first-quarter growth despite declining organic unit volumes and weakness in the core e.l.f. brand; Rhode is launching in Sephora stores in 19 European countries this autumn.

Analysis

The key distinction is earnings quality, not simply exposure to beauty demand. ULTA’s case depends on retaining share while category growth is mixed; if it does, its scale and multi-brand assortment may let it capture demand shifting between prestige and mass without requiring a broad category rebound. The risk is that slower second-half growth exposes how much of the recent resilience came from share gains versus durable basket growth. EL offers greater recovery torque, but the China/fragrance-led improvement is vulnerable to a narrow-category reversal; a low comparison base can make early progress look more durable than it is. For ELF, Rhode’s international rollout can extend growth, but declining organic unit volumes in the core brand and a tariff-refund contribution raise the bar for judging underlying demand. Sephora distribution is a catalyst, not proof of sustained sell-through.

Over 1–3 months, watch ULTA’s forward guidance and comparable sales, EL’s margin progression and China demand, and ELF’s organic volumes and Rhode sell-through. Over 6–18 months, the central question is whether premium recovery broadens beyond fragrance and whether ELF can replenish core-brand demand as Rhode scales. The consensus risk is treating three different drivers as one sector call. Analyst rankings alone do not establish valuation support; absent valuation and expectations data, favor confirmation and relative monitoring over an outright sector bet.

Key Decisions for Investors

• Prefer ULTA as the cleaner execution watchlist name, not an automatic chase: add only if subsequent results support share gains without weakening comparable-sales or guidance trends. Reassess if management’s growth outlook deteriorates or share gains fail to persist.
• Keep EL as a conditional recovery trade rather than buying the turnaround narrative outright. Seek confirmation that margin rebuilding broadens beyond fragrance and that China contributes sustainably; a renewed slowdown in either would undermine the thesis.
• Treat ELF as the highest execution-risk name of the three. Track organic unit volumes separately from reported sales, Rhode sell-through across new Sephora markets, and the normalization of tariff refunds; fading Rhode momentum alongside continued core weakness would be a thesis warning.
• No sector-wide long or forced pair is warranted from this information alone. Before expressing relative value between ULTA, EL, and ELF, verify current valuation, positioning, and earnings expectations; those missing inputs could materially change the risk/reward.